Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Uncover the best high cash back cards that charge no annual fees. Maximize your rewards while keeping your costs down.
28,270 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A leading XRPL validator announced opposition to additional reserve reductions, reviving a divide in the community ov...
Pi Network pushes forward with key KYC milestones as the Core Team signals momentum in its comeback. Over 18 million ...
Bitcoin fell to a two-week low as leveraged bets were wiped out and risk appetite faded amid geopolitical tensions an...
Bitcoin slipped below a key resistance area, opening a test of a critical support confluence around $70k-$72k. Analys...
Solana is slipping as broader crypto markets pull back, with traders weighing key support levels and evolving ETF flo...
NVIDIA has slipped about 17% from its May high, leaving investors debating whether the AI powerhouse is finally a bar...
DraftKings fights for growth across shifting state rules and expanding iGaming. This article breaks down what to watc...
Bitcoin holds a tight $60,000 to $70,000 range as on-chain stress signals mount, signaling the bottom may not yet be ...
A Vanity Fair feature on crypto’s push for legitimacy sparked swift backlash and a heated debate about how the indust...
XRP faces a divided market: ETF demand wanes and hodlers split on the near-term fate. The coin sits near a key suppor...
Ethereum wraps up Q2 with its third consecutive quarterly loss, signaling deeper trouble for the crypto market. Trade...